Tina S. Ipe
Associate Professor and Medical Director for the UAMS Blood Bank and Transfusion Division
Also affiliated: Scripps Research Institute (2021); Houston Methodist (2014–2019); Children's Hospital of Philadelphia (2014); New York Blood Center (2014); Harvard University (2005); Massachusetts General Hospital (2005); Oklahoma Blood Institute (2022–2024); Scripps Clinic (2021)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Tina S. Ipe's research focuses on transfusion medicine and therapeutic apheresis, particularly plasma exchange. Her work has investigated the application of plasma exchange in various medical conditions, including myasthenia gravis and heparin-induced thrombocytopenia. She has also examined the management of anticoagulation in patients undergoing therapeutic plasma exchange and the status of hospital-based blood transfusion services globally. Dr. Ipe's publications include a systematic literature review and meta-analysis on therapeutic plasma exchange for myasthenia gravis and a review on anticoagulation management during plasma exchange. She has also published on electronic patient identification to reduce laboratory errors and on the efficacy of oncolytic viruses for prostate cancer in mouse models. Dr. Ipe's scholarship metrics include an h-index of 16, with 57 total publications and 777 total citations.
Metrics
- h-index: 16
- Publications: 57
- Citations: 780
Positions
-
Associate Professor and Medical Director for the UAMS Blood Bank and Transfusion Division publications 2019–2026University of Arkansas for Medical Sciences Institution web page
Selected Publications
-
Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee (2026)
-
A low dose is better than no dose: Is it time to consider lowering the US minimum plateletpheresis yield? (2026)
-
Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee (2025)
-
Transfusion Efficacy and Safety of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells: Results of a Randomized, Controlled Phase III Trial (2024)
-
Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score Analysis (2024)
-
Current advances in 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee (2024)
-
A review and analysis of outcomes in randomized clinical trials of plasma transfusion in patients with bleeding or for the prevention of bleeding: The BEST collaborative study (2024)
-
Gender differences in scholarly productivity of early‐career transfusion medicine physicians (2024)
-
Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study—protocol for a phase 3, randomized, controlled trial (2023)
-
Evaluation of the Efficacy & Safety of Amustaline/Glutathione Pathogen Reduced RBCs in Complex Cardiac Surgery: the Red Cell Pathogen Inactivation (ReCePI) Study - Protocol for a Phase 3, Randomized, Controlled Trial (2023)
-
Transfusion medicine research in Africa: Insights from investigators in the field (2023)
-
Cold stored platelets – Increasing understanding and acceptance (2023)
-
Academic Productivity of Early Career Transfusion Medicine Specialists: A Workforce Study (2022)
-
Incidence of Red Cell Antibody Formation Following Massive Transfusion Protocol: Experience of a Single Institution (2022)
-
Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19 (2022)
Collaboration Network
Top Collaborators
- Status of hospital-based blood transfusion services in low-income and middle-income countries: a cross-sectional international survey
- Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee
- Current advances in 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- The Status of Transfusion Services in Low- and Middle-Income Nations: a Cross-Sectional International Survey
Showing 5 of 6 shared publications
- Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence
- Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin‐induced thrombocytopenia: A systematic review
- Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee
- Use of therapeutic plasma exchange for pediatric neurological diseases
- Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score Analysis
- Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19
- Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
- Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
- Current advances in 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study—protocol for a phase 3, randomized, controlled trial
- Cold stored platelets – Increasing understanding and acceptance
- Evaluation of the Efficacy & Safety of Amustaline/Glutathione Pathogen Reduced RBCs in Complex Cardiac Surgery: the Red Cell Pathogen Inactivation (ReCePI) Study - Protocol for a Phase 3, Randomized, Controlled Trial
- Transfusion Efficacy and Safety of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells: Results of a Randomized, Controlled Phase III Trial
- A low dose is better than no dose: Is it time to consider lowering the US minimum plateletpheresis yield?
- Status of hospital-based blood transfusion services in low-income and middle-income countries: a cross-sectional international survey
- COVID‐19 and the impact on blood availability and transfusion practices in low‐ and middle‐income countries
- Transfusion medicine research in Africa: Insights from investigators in the field
- The Status of Transfusion Services in Low- and Middle-Income Nations: a Cross-Sectional International Survey
- Status of hospital-based blood transfusion services in low-income and middle-income countries: a cross-sectional international survey
- COVID‐19 and the impact on blood availability and transfusion practices in low‐ and middle‐income countries
- Transfusion medicine research in Africa: Insights from investigators in the field
- The Status of Transfusion Services in Low- and Middle-Income Nations: a Cross-Sectional International Survey
- Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study—protocol for a phase 3, randomized, controlled trial
- Plasma Adsorption with the MTx.100 Column in Critically Ill COVID-19 Patients: A Prospective Study and Propensity Score Analysis
- Evaluation of the Efficacy & Safety of Amustaline/Glutathione Pathogen Reduced RBCs in Complex Cardiac Surgery: the Red Cell Pathogen Inactivation (ReCePI) Study - Protocol for a Phase 3, Randomized, Controlled Trial
- Transfusion Efficacy and Safety of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells: Results of a Randomized, Controlled Phase III Trial
- Current advances in 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- A low dose is better than no dose: Is it time to consider lowering the US minimum plateletpheresis yield?
- Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee
- Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin‐induced thrombocytopenia: A systematic review
- Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee
- Use of therapeutic plasma exchange for pediatric neurological diseases
- Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin‐induced thrombocytopenia: A systematic review
- Current advances in 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- The impact of COVID‐19 on academic productivity by female physicians and researchers in transfusion medicine
- Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19
- Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
- Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
- Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19
- Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
- Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
- Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19
- Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
- Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
Similar Researchers
Based on overlapping research topics